Molecular Evaluation of PROGINS Mutation in Progesterone Receptor Gene and Determination of its Frequency, Distribution Pattern and Association with Breast Cancer Susceptibility in Saudi Arabia

被引:6
作者
Albalawi, Ibrahim A. [1 ]
Mir, Rashid [2 ]
Abu-Duhier, Fasel M. [2 ]
机构
[1] Univ Tabuk, Fac Med, Dept Surg Oncol, Tabuk 71491, Saudi Arabia
[2] Univ Tabuk, Fac Appl Med Sci, Dept Med Lab Technol, Prince Fahd Bin Sultan Res Chair, Tabuk 71491, Saudi Arabia
关键词
Breast cancer; progesterone receptor (PR) gene; PROGINS mutation; PgR (i 331C>T); progesterone receptor -PRA; and PRB; gene variation; HORMONE-THERAPY; OVARIAN-CANCER; RISK; POLYMORPHISM; EXPRESSION; ESTROGEN; METABOLISM; PATHWAYS; PROMOTER; SUBTYPE;
D O I
10.2174/1871530319666191125153050
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: Experimental and clinical evidence demonstrate that progesterone hormone and its nuclear receptor, the Progesterone Receptor (PR), play critical role in controlling mammary gland Yumorigenesis and breast cancer development. Hormonal therapy (Tomaxifen) is the frontline treatment for hormone -dependent breast cancers. Progesterone hormone induces its action on the target cells by binding with its Progesterone receptor (PgR) therefore any genetic variations, which might induce alienation in the progesterone receptor, can result in an increased susceptibility of gynecological cancers. Alu insertion (PROGINS) mutation in PgR gene is reported to be associated with an increased risk of ovarian cancer and a decreased risk of breast cancer. However, its association with breast cancer risk remains inconclusive. Therefore, we investigated the association of PROGINS allele and its link with breast cancer risk. Methods: This case control study was performed on 200 subjects in which 100 were breast cancer cases and 100 gender matched healthy controls.The mutation was detected by using mutation specific Results: A clinically significant difference was reported in genotype distribution of PROGINs allele among the cases and gender -matched healthy controls (P<O, 032'). Genotype frequencies of Al/A1, Al/A2, A2/A2 reported in cases was 81,"O, 19% (18% & l,"O) and in matched healthy controls were 93%, 7 s (6% & 1 7'0). The higher frequency of PROGINs allele (19%) was observed in cases than the healthy controls (70,/o). The findings indicated that PgR variants (CC vs CT) increased the risk of Breast cancer in codominant inheritance model with OR= 3.44, 95% CI =1. 30-9.09, P<0.021) whereas nonsignificant association was found for CC vs TT genotypes with OR=1.14, 95% C1=0.07-18.658, PA. 92. Ilowover, subgroup analysis revealed that CT TT vs CC' genotype increased the risk of breast cancer in dominant inheritance model tested OR 3. 11, 95% CI (1.24-7.79), P 0.015). A nonsignificant association for PgR (CC -CT) vs TT) genotypes were reported in breast cancer OR = 1. 0. 95% CI (0. 061-16.21), P-1) in recessive inheritance model tested. However, analysis with clinicalpathological variables revealed that the PROGINs allele is significantly associated with the distant metastasis and advanced stage of the disease. Conclusion: The mutation specific PCR was successfully developed as an alternative to Sanger sequencing for the cost-effective detection for PROGINS allele of progesterone receptor gene. A clinically significant correlation of PROGINs allele was reported with the distant metastasis and advanced stage of the disease. Taken together, these results demonstrated that PROGINS variant is associated with an increased susceptibility to Breast cancer, providing novel insights into the genetic etiology and underlying biology of Breast carcinogenesis. Further studies with large sample sizes are required to validate our findings.
引用
收藏
页码:760 / 770
页数:11
相关论文
共 48 条
  • [11] Feigelson HS, 2004, CANCER EPIDEM BIOMAR, V13, P1084
  • [12] Progesterone Receptor Gene Variants in Metastatic Estrogen Receptor Positive Breast Cancer
    Fowler, Amy M.
    Salem, Kelley
    DeGrave, Michael
    Ong, Irene M.
    Rassman, Shane
    Powers, Ginny L.
    Kumar, Manoj
    Michel, Ciara J.
    Mahajan, Aparna M.
    [J]. HORMONES & CANCER, 2020, 11 (02): : 63 - 75
  • [13] GHALI RM, 2018, PATHOL ONCOL RES
  • [14] Progesterone, progestins and the breast in menopause treatment
    Gompel, A.
    Plu-Bureau, G.
    [J]. CLIMACTERIC, 2018, 21 (04) : 326 - 332
  • [15] Estrogen and progesterone signalling in the normal breast and its implications for cancer development
    Hilton, Heidi N.
    Clarke, Christine L.
    Graham, J. Dinny
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2018, 466 : 2 - 14
  • [16] GATA5 activation of the progesterone receptor gene promoter in breast cancer cells is influenced by the+331G/A polymorphism
    Huggins, GS
    Wong, JYY
    Hankinson, SE
    De Vivo, I
    [J]. CANCER RESEARCH, 2006, 66 (03) : 1384 - 1390
  • [17] Progesterone involvement in breast development and tumorigenesis - as revealed by progesterone receptor "knockout" and "knockin" mouse models
    Ismail, PM
    Amato, P
    Soyal, SM
    DeMayo, FJ
    Conneely, OM
    O'Malley, BW
    Lydon, JP
    [J]. STEROIDS, 2003, 68 (10-13) : 779 - 787
  • [18] Progesterone induction of calcitonin expression in the murine mammary gland
    Ismail, PM
    DeMayo, FJ
    Amato, P
    Lydon, JP
    [J]. JOURNAL OF ENDOCRINOLOGY, 2004, 180 (02) : 287 - 295
  • [19] Progesterone receptor polymorphisms and risk of breast cancer: results from two Australian breast cancer studies
    Johnatty, Sharon E.
    Spurdle, Amanda B.
    Beesley, Jonathan
    Chen, Xiaoqing
    Hopper, John L.
    Duffy, David L.
    Chenevix-Trench, Georgia
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2008, 109 (01) : 91 - 99
  • [20] Use of spectroscopic and zeta potential techniques to study the interaction between lysozyme and curcumin in the presence of silver nanoparticles at different sizes
    Kamshad, Maryam
    Talab, Mahtab Jahanshah
    Beigoli, Sima
    Sharifirad, Atena
    Chamani, Jamshidkhan
    [J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2019, 37 (08) : 2030 - 2040